The heterogeneity of breast cancer, with various subtypes such as triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, further complicates therapeutic approaches [3,4]. Here, ERBB2 is linked to triple-negative breast carcinoma.